Virological patterns of HCV patients with failure to interferon‐free regimens

Virological patterns of HCV patients with failure to interferon‐free regimens AbbreviationsDAAdirectly acting antiviralHCVhepatitis C virusIFNpegylated interferon alphaPCRpolymerase chain reactionRASresistance‐associated substitutionsRBVribavirinSVRsustained viral responseINTRODUCTIONThe World Health Organization has estimated that 71 million people are infected with hepatitis C virus (HCV) worldwide and that more than 399 000 people die each year of HCV‐related liver diseases. Chronic hepatitis by HCV infection is characterized by an indolent course or a slow progression to liver cirrhosis and hepatocellular carcinoma.For many years, pegylated interferon alpha (IFN) plus ribavirin (RBV) combination therapy was the standard treatment for HCV infection. This combination therapy provided a sustained clearance of circulating HCV (sustained viral response—SVR) in half of the patients infected with HCV‐genotype 1, in around 70% of those with HCV‐genotype 2 and around 60% of those with HCV‐genotype 3; however, the frequency and severity of the side‐effects (flu‐like symptoms, depression, cytopenia, and hemolytic anemia) made this therapy burdensome for many patients.Recently, regimens without interferon, which combine several classes of directly acting antiviral agents (DAAs), have improved the response rate and tolerability also in difficult‐to‐treat patients such as patients with an advanced liver disease. In fact, these IFN‐free regimens yield SVR rates of approximately 95%, even in patients with cirrhosis.Despite the excellent efficacy of DAAs, some patients (around 5%) still http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Medical Virology Wiley
Loading next page...
 
/lp/wiley/virological-patterns-of-hcv-patients-with-failure-to-interferon-free-wtucCWxKGr
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0146-6615
eISSN
1096-9071
D.O.I.
10.1002/jmv.25022
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsDAAdirectly acting antiviralHCVhepatitis C virusIFNpegylated interferon alphaPCRpolymerase chain reactionRASresistance‐associated substitutionsRBVribavirinSVRsustained viral responseINTRODUCTIONThe World Health Organization has estimated that 71 million people are infected with hepatitis C virus (HCV) worldwide and that more than 399 000 people die each year of HCV‐related liver diseases. Chronic hepatitis by HCV infection is characterized by an indolent course or a slow progression to liver cirrhosis and hepatocellular carcinoma.For many years, pegylated interferon alpha (IFN) plus ribavirin (RBV) combination therapy was the standard treatment for HCV infection. This combination therapy provided a sustained clearance of circulating HCV (sustained viral response—SVR) in half of the patients infected with HCV‐genotype 1, in around 70% of those with HCV‐genotype 2 and around 60% of those with HCV‐genotype 3; however, the frequency and severity of the side‐effects (flu‐like symptoms, depression, cytopenia, and hemolytic anemia) made this therapy burdensome for many patients.Recently, regimens without interferon, which combine several classes of directly acting antiviral agents (DAAs), have improved the response rate and tolerability also in difficult‐to‐treat patients such as patients with an advanced liver disease. In fact, these IFN‐free regimens yield SVR rates of approximately 95%, even in patients with cirrhosis.Despite the excellent efficacy of DAAs, some patients (around 5%) still

Journal

Journal of Medical VirologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off